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The Epstein–Barr virus (EBV) immediate-early (IE) protein, BZLF1 (Z), initiates the switch from latent to lytic infection. Z
transactivation of an early viral promoter, BMRF1, is relatively inefficient in lymphoid cells (compared with epithelial cells),
unless the other EBV IE protein, BRLF1, is also present. Cellular proteins, including the p65 component of NF-kB, have
been shown to interact directly with Z in vitro through the bZip dimerization domain and inhibit Z-induced transactivation.
Here we precisely define a residue within the bZip dimerization domain of Z (amino acid 200) which is required for interaction
in vitro with the p65 component of NF-kB, but is not essential for Z homodimerization. In lymphoid cells, a Z mutant which
has been altered at amino acid 200 (tyrosine to glutamic acid) transactivates both the early BMRF1 promoter and the
immediate-early BZLF1 promoter (Zp) four- to fivefold better than wild-type Z. In contrast, mutation of amino acid 200 does
not affect Z transactivator function in epithelial cells. The results suggest that Z function is specifically inhibited by a
lymphoid-specific protein(s) through amino acid 200 in the bZip dimerization domain. Modulation of Z’s activator function
may help to regulate the stringency of viral latency in lymphocytes. q 1997 Academic Press
INTRODUCTION (Chang et al., 1990; Farrell et al., 1989; Flemington and
Speck, 1991; Kouzarides et al., 1991). Z transcriptionally
Epstein–Barr virus (EBV) is a human herpesvirus
activates early viral promoters by directly binding as a
which infects B and T lymphocytes and certain epithelial
homodimer to upstream Z-response elements (ZREs),
cells (Rickinson and Kieff, 1996). EBV infection is strongly
which are similar (sometimes identical) to AP1-bindingassociated with the development of several human ma-
motifs (Chang et al., 1990; Chevallier-Greco et al., 1989;lignancies, including Burkitt’s lymphoma and nasopha-
Chi et al., 1995; Cox et al., 1990; Farrell et al., 1989;ryngeal carcinoma (Rickinson and Kieff, 1996; Zur Hau-
Flemington and Speck, 1990; Kenney et al., 1989a,b; Lie-sen et al., 1970). In B lymphocytes, which are immortal-
berman and Berk, 1990; Lieberman et al., 1990; Packhamized by EBV, as well as in T cells, viral infection is usually
et al., 1990; Quinlivan et al., 1993; Rooney et al., 1989;latent, with only limited viral gene expression (Kieff, 1996;
Urier et al., 1989). Dimerization of Z is essential for itsRickinson and Kieff, 1996). In contrast, EBV infection in
DNA-binding activity, as well as its transactivator func-epithelial cells frequently results in viral replication and
tion. Although the dimerization domain of Z does notproduction of infectious virions (Kieff, 1996; Li et al., 1992;
possess typical heptad leucine repeats, dimerization oc-Rickinson and Kieff, 1996; Sixby et al., 1984). Thus, cellu-
curs through a coiled-coil type interaction (Chang et al.,lar factors must regulate the stringency of viral latency.
1990; Flemington and Speck, 1991; Kouzarides et al.,In vitro, overexpression of the EBV immediate-early
1991; Lieberman and Berk, 1991).gene, BZLF1, is sufficient to initiate the switch from latent
Given the ability of the BZLF1 gene product to disruptto lytic infection (Chevallier-Greco et al., 1986; Country-
viral latency, cellular regulation of Z function is likely toman and Miller, 1985; Kenney et al., 1989; Rooney et al.,
play a key role in modulating the stringency of viral latency.1988, 1989; Takada et al., 1986). Agents which induce
We have reported that Z-induced transactivation of theBZLF1 transcription, including 12-O-tetradecanoylphor-
BMRF1 early promoter is cell-type specific (Holley-Guthriebol-13-acetate (TPA) and anti-immunoglobulin, disrupt vi-
et al., 1990; Quinlivan et al., 1993). Whereas Z alone canral latency (Flemington et al., 1991B; Laux et al., 1988;
maximally activate expression of the BMRF1 early pro-Rickinson and Kieff, 1996; Takada et al., 1989; Zur Hau-
moter in certain epithelial cell lines (i.e., HeLa and Hep-2sen et al., 1979). The BZLF1 (Z) protein is considered to
cells), efficient activation of the same promoter requiresbe a member of the bZip superfamily based on its se-
both Z and another EBV immediate-early protein, BRLF1quence and structural similarity with other bZip proteins
(R) (Hardwick et al., 1988), in other cell lines (the Jurkat T-
cell line and the EBV-negative Louckes B-cell line) (Holley-1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (919) 966-3015. Guthrie et al., 1990; Quinlivan et al., 1993).
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Z interacts directly with several different cellular pro- Model 373A DNA Sequencer using the Taq DyeDeoxy
Terminator Cycle Sequencing Kit (Applied Biosystems).teins, including the NF-kB transcription factor, the p53
tumor suppressor protein, and the RAR and RXR retinoic Z200E contains a tyrosine to glutamic acid mutation at
amino acid 200, and Z225E contains a leucine to glutamicacid receptors (Gutsch et al., 1994; Sista et al., 1993,
1995; Zhang et al., 1994). Each of these interactions re- acid mutation at amino acid 225 (Fig. 1B). The mutants
(constructed within the BZLF1 in vitro translation vector,quires the bZip dimerization domain of Z and results in
inhibition of Z transactivator function. The inhibition of Z pSP64) were subsequently cloned into the pHD1013
expression vector (a gift from E. S. Huang), downstreamfunction by NF-kB (or other members of the rel protein
family) could potentially be mediated in a cell-specific of cytomegalovirus immediate-early promoter (pCMV-
Z200E and pCMV-225E), and the PGEX-3X vector (Phar-fashion. In most cell types, NF-kB is retained in the cyto-
plasm as an inactive complex with its inhibitory protein, macia, Alameda, CA), in-frame and downstream of the
glutathione S-transferase (GST) protein (pGST-Z200E andIkB (Baeuerle, 1991; Baeuerle and Baltimore, 1988; Beg
et al., 1992; Lenardo and Baltimore, 1989). However, in pGST-Z225E).
The promoter plasmids, BMRF1-CAT, BMRF1-DAP1-B cells, a certain amount of NF-kB is present in the
nucleus constitutively as a heterodimer of the p50 and CAT, BMRF1-DZRE-CAT (previously named BMRF1-D106),
and BMRF1-DAP1/ZRE (previously named BMRF1-DAP1/p65 subunits (Lenardo and Baltimore, 1989).
Here we have more precisely mapped the domain(s) 106) have been described (Quinlivan et al., 1993). The
BMRF1-CAT vector contains the EBV early BMRF1 pro-of Z required for direct interaction with the p65 compo-
nent of NF-kB and have constructed a Z protein (mutated moter linked to the chloramphenicol acetyltransferase
(CAT) gene in the Bluescript SK(/) phagemid vectorat amino acid 200) which retains transactivator function,
but no longer interacts efficiently with NF-kB. The pheno- (Stratagene). The BMRF1-DAP1-CAT, BMRF1-DZRE-
CAT, and BMRF1-DAP1/ZRE-CAT constructs containtype of this mutant Z protein is cell-type specific and
modulated by the presence of the other EBV IE protein, point mutations of the BMRF1 promoter in the AP1 site
(located at 060 relative to the mRNA start site), anR. In lymphoid cells, the transcriptional activator function
of the mutant Z protein is four- to fivefold greater than upstream ZRE site (located at 0106), or both the AP1
and the ZRE sites, respectively (Quinlivan et al., 1993).that of the wild-type protein. In epithelial cells, the mutant
and wild-type proteins have similar transactivator func- The Z-CAT plasmid was constructed by insertion of the
BZLF1 promoter (103,625 – 103,181) into the pCAT3Mtion. Our results suggest that Z is negatively regulated
in a lymphoid-specific fashion by a cellular protein (po- vector, upstream of the CAT gene as described before
(Kenney et al., 1989b).tentially NF-kB or other members of the rel family)
through amino acid 200 within the dimerization domain. The expression plasmid pCMV-Z has been previously
described (Quinlivan et al., 1993) and contains the BZLF1
cDNA in the pHD1013 vector (a gift from E. S. Huang),MATERIALS AND METHODS
under the control of cytomegalovirus immediate-early
Cell lines promoter. The pCMV-R plasmid contains the BRLF1 gene
linked to the CMV-IE promoter in the pUC18 vector asThe cell lines used include the EBV-negative Burkitt’s
described before (Quinlivan et al., 1993). The GST-p65lymphoma cell line, DG75, the EBV-positive Burkitt’s
plasmid was created by insertion of the intact p65 codinglymphoma cell line, Raji, the human T-cell line, Jurkat, and
sequence downstream of the GST protein in the pGEX-the human cervical epithelial cell line, HeLa. Lymphoid
1N vector (AMRAD Corp.) as described (Gutsch et al.,cell lines were propagated in RPMI 1640 medium (GIBCO,
1994; Stein et al., 1993).Gaithersburg, MD) supplemented with 10% fetal bovine
The plasmid CMV-Z311 (derived from the SV40-drivenserum. The HeLa cell line was maintained in Dulbecco’s
Z311 vector, a gift from Alain Sergeant) (Giot et al., 1991)modified Eagle’s medium H supplemented with 10% fetal
contains the Z cDNA, with a site-directed mutation (anbovine serum. All cell lines were maintained at 377 in a
alanine to lysine switch at amino acid 185) within thehumidified atmosphere containing 5% CO2 .
DNA-binding domain, cloned into the pHD1013 vector.
This mutation greatly reduces the DNA-binding functionPlasmids
of Z without affecting nuclear localization (Giot et al.,
1991). The plasmid CMV-Z200E/311 contains both theThe double point mutants of BZLF1 were gifts from Erik
Flemington and Sam Speck and have been described Z311 mutation (amino acid 185) and the Z200E mutation
(amino acid 200).previously (Flemington and Speck, 1991). Single amino
acid mutants of BZLF1 were made using the Transformer
Site-Directed Mutagenesis kit (Clontech, Palo Alto, CA) DNA preparation and transfection
as specified by the manufacturer’s instructions. The final
mutants were confirmed by DNA sequencing done at the Plasmid DNA was purified using the Qiagen Maxi kit
(Qiagen, Chatsworth, CA) as specified by the manufac-UNC-CH Automated DNA Sequencing Facility on a
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turer. Transfection of DNA into both lymphoid and epithe- 0.1% SDS–8% polyacrylamide gel and submitted to auto-
radiography (enhanced with 1 M sodium salicylate forlial cell lines was accomplished by electroporation (Ton-
neguzzo et al., 1986). For each condition, 107 cells were 35S-labeled proteins).
shocked at 1500 V, using the Zapper electroporation unit
Electromobility shift assays (EMSAs)(Medical Electronics Shop, University of Wisconsin). Epi-
thelial cells were harvested and resuspended in RPMI
Electromobility shift assays were performed as pre-
1640 medium for electroporation.
viously described (Garner and Revzin, 1981). The syn-
thetic double-stranded oligonucleotides used in bindingCAT assays
reactions were end-labeled with 32P. The double ZRE
Cell extracts were prepared 48 hr after transfection probe (5*GATCATGTGCAAGCTATGTGCAATG3*) con-
and incubated at 377 with [14C]chloramphenicol in the tains two ZRE binding sites. Nuclear extracts were made
presence of acetyl coenzyme A as described previously by lysing cells in a buffer containing 10 mM Tris (pH 8.0),
(Gorman et al., 1982). The percentage of acetylation of 60 mM NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF,
chloramphenicol was quantitated by thin-layer chroma- and 0.5% NP-40, followed by centrifugation to separate
tography followed by PhosphorImager screening (Molec- cytoplasm and nuclear portions. The nuclear portion was
ular Dynamics). then resuspended in 20 mM HEPES (pH 7.9), 0.75 mM
spermidine, 0.2 mM EDTA, 2 mM DTT, 1 mM PMSF, 20%
Z protein expression glycerol, and 0.4 M NaCl and rotated at 47 for 30 min
followed by centrifugation for 10 min. The resultant su-The plasmids used for in vitro translation of wild-type
pernatant was used in electromobility shift assays. TheZ protein contain the BZLF1 cDNA within the pSP64 (Pro-
in vitro translated proteins and GST proteins were mademega) phagemid vector (a gift from P. Farrell). The plas-
as described before.mids were digested with EcoRI restriction enzyme, tran-
The EMSA binding reactions were conducted in ascribed by SP6 polymerase (Promega), and then trans-
buffer consisting of 100 mM KCl, 20 mM HEPES (pH 7.3),lated in the presence of 35S-labeled methionine using a
10% glycerol, 0.2 mM EDTA, 4 mM DTT, 0.5 mM PMSFrabbit reticulocyte lysate system (Promega).
with 2 mg of poly(dI–dC)rpoly(dI–dC) (Pharmacia). FiveThe construction of the plasmid glutathione S-transferase
microliters of in vitro translated protein, or 10 mg of nu-(GST)–Z has been described previously (Gutsch et al.,
clear extract protein, was added to each reaction and1994). The GST–Z plasmid contains the full-length BZLF1
incubated at room temperature for 15 min prior to addingcDNA inserted downstream (in-frame) of the GST gene in
the labeled probe. For the competition binding assay, 0,the pGEX-3X vector (Pharmacia). The bacterial proteins
10, 50, or 1001 unlabeled AP1 oligonucleotide (Promega)were induced by 1 mM isopropylthiogalactopyranoside
was added into the preincubation reactions. The labeled(IPTG) for 2–3 hr at 377. Bacteria were pelleted, resus-
probe (20,000 cpm) was then added and further incu-pended in phosphate-buffered saline (PBS), sonicated, and
bated for an additional 15 min at room temperature. Thecleared by centrifugation (Smith and Johnson, 1987).
reaction mixture was loaded onto a 5% polyacrylamide
gel and run in 0.51 Tris–borate buffer at 47.GST fusion protein affinity chromatography
The interaction of 35S-labeled in vitro translated wild- Coimmunoprecipitation and immunoblotting analysis
type or mutant Z proteins with the GST–Z and GST–p65
fusion proteins was analyzed by affinity chromatography To assess the stability of wild-type and mutant Z pro-
teins, DG75 cells were transfected with the pHD1013as previously described (Artandi and Calame, 1993;
Smith and Johnson, 1987). For each condition, 0.3 ml vector, the wild-type Z vector, or the Z200E vector. Five
hours posttransfection, cells were treated with 50 mg/mlof bacterial culture containing GST fusion proteins was
incubated with 50 ml of 50% glutathione–agarose beads cyclohexamide. Transfected cell extracts were prepared
immediately prior to cyclohexamide treatment (Time 0)(Sigma) for 30 min at room temperature. The coated
beads were washed three times with 1 ml of 11 PBS. and at 24 and 48 hr posttreatment. Protein extracts were
separated on an 8% denaturing polyacrylamide gel andThe purified beads were then resuspended in 0.5 ml
buffer containing 20 mM N-2-hydroxyethylpiperazine-N*- electrophoretically transferred to a nitrocellulose mem-
brane. Transfected Z protein was quantitated using an2-ethanesulfonic acid (HEPES; pH 7.7), 25 mM NaCl, 2.5
mM MgCl, 0.1 mM EDTA, 1 mM dithiothreitol (DTT), 0.05% ECL Western blot kit (Amersham) according to the manu-
facturer’s specifications. The membrane was blockedNonidet-P40 (NP-40) and incubated with 10 ml of in vitro
translated proteins. The binding reactions were con- with 5% nonfat milk and probed with the anti-Z mono-
clonal antibody BZ.1 [a gift from A. Rickinson (Young etducted at room temperature for 1 hr or at 47 overnight.
The bead complexes were washed five times in 1 ml of al., 1991)] at a 1:50 dilution. A goat anti-mouse k-chain
immunoglobulin conjugated with horseradish peroxidasethe above buffer and boiled in SDS–loading buffer. The
bound in vitro translated proteins were separated on a (Southern Biotechnology Associates, Inc., Birmingham,
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AL) was used as the secondary antibody at a 1:2000 petent, are able to dimerize to Z (although the Z200E/
Z225E mutant dimerizes less efficiently than wild-type Z)dilution. Proteins were detected by luminescence re-
agent and exposed to X-ray film. but no longer bind to p65 (Fig. 1C). We are uncertain why
we did not detect dimerization with these mutants in theCoimmunoprecipitation was performed on DG75
cells transfected with the Z wild-type or Z200E expres- previous studies, but the present results agree with those
of Sista et al. (1995).sion plasmids (alone or cotransfected with the p65
expression vector). The cells were harvested 24 hr after These results suggest that the ability of Z to interact
with p65 in vitro can be separated from its homodimer-transfection, resuspended in 250 ml buffer [20 mM N-2-
hydroxyethylpiperazine-N*-2-ethanesulfonic acid (HEPES; ization potential. To map the exact residue(s) required
for p65 interaction, we generated single amino acidpH 7.7), 25 mM NaCl, 2.5 mM MgCl, 0.1 mM EDTA,
1 mM dithiothreitol (DTT), 0.05% NP-40], followed by mutations in Z residues 200 (containing a tyrosine to
glutamic acid conversion) and 225 (containing a leu-sonication and centrifugation to remove cellular de-
bris. Sixty micrograms of protein in each condition was cine to glutamic acid change) and tested these pro-
teins for their ability to homodimerize and interact withincubated with 15 ml of polyclonal anti-p65 rabbit anti-
body (Santa Cruz Biotechnology) or 30 ml normal rabbit p65 (Z197/200S was not studied because it is defec-
tive in DNA binding) (Sista et al., 1995). As shown inserum in a total volume of 250 ml of the resuspension
buffer. The reaction was rocked at 47 for 1 hr. Forty Fig. 1D, each of these mutants could homodimerize
as efficiently as wild-type Z (as indicated by the abilitymicroliters of 50% protein A – Agarose (Sigma) beads
were added and rotated for another hour. The beads to bind to GST – Z-coated agarose beads). Although
both wild-type Z and the Z225E mutant could bind effi-were washed three times with the same buffer, resus-
pended in 20 ml 21 SDS – PAGE loading buffer, sepa- ciently with the GST – p65 fusion protein, the interac-
tion of Z200E with p65 was much weaker, indicatingrated on an 8% polyacrylamide gel, and transferred to
a nitrocellulose membrane, followed by Western immu- that the Z amino acid 200 contributes significantly to
the interaction with p65.noblot detection with the anti-Z monoclonal antibody
BZ.1 as described above. To confirm that the Z200E mutant also interacts less
efficiently with p65 in vivo, DG75 cells were trans-
fected with the Z wild-type and Z200E expression vec-RESULTS
tors either alone or in combination with a p65 expres-
The BZLF1 protein interacts with NF-kB p65 in a
sion vector (Fig. 1E). Protein extracts were immuno-
region which is not required for Z dimerization
precipitated with a rabbit polyclonal antibody directed
against p65, or normal rabbit serum, and then probedPreviously, we have demonstrated that Z interacts di-
rectly with the p65 component of NF-kB in vitro and that for the presence of coprecipitated Z using immunoblot
analysis. A small amount of the wild-type Z was copre-overexpression of p65 in vivo inhibits Z transactivator
function (Gutsch et al., 1994). The bZip dimerization do- cipitated by the p65 antibody in the absence of co-
transfected p65 (presumably reflecting the interactionmain of Z is required for direct interaction with the rel
homology domain of p65 (Gutsch et al., 1994). To map of Z with the endogenous nuclear p65), and a greater
amount was coprecipitated in the presence of cotrans-precisely the critical amino acid residues of Z required
for p65 binding, a series of Z proteins containing point fected p65. In contrast to wild-type Z, no detectable
Z200E was precipitated by the p65 antibody in themutations in the bZip dimerization domain was examined
for the ability both to homodimerize and to heterodimer- absence of cotransfected p65. In the presence of co-
transfected p65, Z200E was coprecipitated much lessize with p65 in vitro by affinity chromatography assays
(Figs. 1A–1C) (Artandi and Calame, 1993). efficiently than wild-type Z. Thus, we have identified
a residue within the Z bZip domain, which, while notAs reported before, two Z proteins (Z214R/218R and
Z214S/218S) containing mutations within the interface of essential for homodimerization of the protein, is prob-
ably involved in its interaction with p65.the coiled-coil helix lost dimerization ability, as well as
interaction with p65 (Fig. 1C, Z214R/218R data not
shown) (Flemington and Speck, 1991; Gutsch et al., DNA-binding ability of BZLF1 mutants
1994). Two Z proteins (Z205R/206D and Z209R/216E) con-
taining mutations predicted to reside on the back of the To determine if the mutant Z200E and Z225E proteins
retain DNA binding ability, electromobility shift assayshelix could homodimerize, as well as interact with GST-
p65 (Figs. 1A–1C). These data are consistent with our were conducted using in vitro translated Z proteins and
a 32P-labeled probe containing two ZRE sites (Fig. 2A).previous findings that BZLF1 dimerization is required for
p65 interaction (Gutsch et al., 1994). However, in contrast The wild-type and mutant in vitro translated Z proteins
bound to the ZRE probe with similar efficiencies (Fig. 2A).to our previous findings (Gutsch et al., 1994), we now
find that two mutant Z proteins (Z197K/200S and Z200E/ Similar results were observed using a probe containing
an AP1 motif (data not shown).225E), which we had reported to be dimerization incom-
AID VY 8413 / 6a29$$$222 01-31-97 20:01:50 vira AP: Virology
40 HONG, HOLLEY-GUTHRIE, AND KENNEY
FIG. 1. Mapping a region in Z which is required for interaction with p65, but not for dimerization. (A) Amino acid sequence comparisons of
the bZip domains in the Z protein and other bZip proteins, GCN4, c-jun, and c-fos. The single-letter amino acid code is used to represent the
sequence. The identical and conserved amino acids are indicated by capital letters. The a and d positions of the leucine zipper (which form
the interface) are in boldface. (B) A series of Z mutations within the bZip dimerization domain was constructed as shown. Each mutant was
tested for the ability to interact with the GST-Z and GST-p65 proteins in affinity chromatography assays as previously described (Artandi and
Calame, 1993; Smith and Johnson, 1987). Results are summarized as positive (////) to negative (0) according to the strength of the
dimerized complex in comparison to the wild-type Z. (C) 3 ml of the in vitro translated 35S-labeled Z wild-type and various Z mutant proteins
were directly loaded onto the gel (lanes 1 to 6). 10 ml of the in vitro translated proteins were incubated with glutathione agarose beads coated
with the GST vector protein (lanes 7 and 14), the GST-Z protein (lanes 8 to 13), or the GST – p65 protein (lanes 15 to 20). The retained in vitro
translated proteins are indicated by an arrow. (D) In vitro translated, 35S-labeled wild-type Z (Zwt), Z200E, and Z225E proteins were directly
loaded onto the gel (lanes 1, 6, and 11, respectively), incubated with glutathione agarose beads alone (lanes 2, 7, and 12), incubated with
GST protein-coated beads (lanes 3, 8, and 13), incubated with GST – Z protein-coated beads (lanes 4, 9, and 14), or incubated with GST – p65
protein-coated beads (lanes 5, 10, and 15). The retained in vitro translated proteins are indicated by an arrow. 3 ml of the reticulocyte extracts
were directly loaded onto the gel, and 10 ml of the extracts were used in the affinity chromatography assays. (E) DG75 cells were transfected
with different expression plasmids as follows: pHD1013 vector (lanes 1, 5, and 11), Z wild-type (lanes 2, 6, and 12), Z200E (lanes 3, 7, and
13), p65 (lanes 4, 8, and 14), Z wild-type plus p65 (lanes 9 and 15), and Z200E plus p65 (lanes 10 and 16). Cells were harvested 24 hr after
transfection and immunoprecipitated with p65-specific rabbit antibody (lanes 11 – 16) or normal rabbit serum (lanes 5 – 10). Lanes 1 – 4 show
the cell lysates directly loaded onto the SDS gel without immunoprecipitation. Immunoprecipitated proteins were separated on an SDS gel,
transferred to nitrocellulose membranes, and then immunoblotted with the anti-Z monoclonal antibody, BZ.1 (Young et al., 1991). The position
of Z protein is indicated.
The in vivo DNA-binding ability of Z200E was also in- Mutation of Z amino acid 200 enhances transactivator
function in a lymphoid-specific fashionvestigated using nuclear extracts from transfected DG75
cells (Fig. 2B) and HeLa cells (Fig. 2C). Although slight
To determine the in vivo phenotype of the Z200E anddifferences in the DNA-binding efficiency of the wild-type
Z225E mutants, we examined the ability of these proteinsand mutant Z proteins were observed in the transfected
to activate an early EBV promoter (BMRF1) in various cellcell extracts from experiment to experiment (presumably
types (Fig. 3A). As we previously reported, wild-type Zreflecting the difficulty of using precisely the same
cannot efficiently transactivate the BMRF1 promoter inamount of the transfected wild-type and mutant Z pro-
the Jurkat T-cell line unless another viral immediate-earlyteins), no consistent differences in the efficiency of wild-
protein, R, is also present (Holley-Guthrie et al., 1990;type versus mutant proteins occurred in either DG75
Quinlivan et al., 1993). Interestingly, transactivation bycells or HeLa cells. We conclude that mutation of amino
the Z200E protein was enhanced fivefold in Jurkat cellsacids 200 and 225 does not significantly affect Z DNA-
binding capability. compared with wild-type Z and was four times stronger
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FIG. 1—Continued
than that of wild-type Z in the EBV-negative B-cell line, tion was decreased significantly more than that of Z200E
(Fig. 3B). However, at higher doses of p65, the wild-typeDG75. In contrast, the transactivator function of Z200E in
the epithelial line, HeLa, was similar to that of wild-type and mutant Z proteins were inhibited to a similar extent
(data not shown). The inhibition of Z200E function byZ. The transactivator function of the Z225E mutant was
comparable to that of wild-type Z in lymphoid cells, al- higher doses of p65 may reflect either nonspecific toxicity
or the fact that this mutant can interact with p65 in vivothough it was less than wild-type Z in epithelial cells (Fig.
3A). These results suggest that mutation of amino acid to a limited extent (Fig. 1E).
The BMRF1 promoter contains both Z- and R-binding200 within the Z dimerization domain enhances Z trans-
activator function in a lymphoid-specific fashion. sites (Quinlivan et al., 1993). We have shown that Z
transactivation of the BMRF1 promoter in lymphoidTo confirm that Z200E is less susceptible than wild-
type Z to the inhibitory effect of p65 (Gutsch et al., 1994), cells (but not epithelial cells) is significantly enhanced
by the presence of the BRLF1 immediate-early genethe ability of wild-type Z versus Z200E to activate the
BMRF1 promoter in DG75 cells was compared in the product (R), even though R alone has little effect on
this promoter (Holley-Guthrie et al., 1990; Quinlivan etpresence and absence of cotransfected p65. In the pres-
ence of low doses of p65, wild-type Z transactivator func- al., 1993). Thus, R binding to the BMRF1 promoter may
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FIG. 2. DNA binding of Z mutants. (A) An electromobility shift assay was performed using proteins in vitro translated in reticulocyte lysates. The
double ZRE oligonucleotide probe, which contains two consensus ZRE-binding sites, was used as the probe. The wild-type Z-binding complex (lane
2) was specifically competed by competitor DNA containing the AP1 motif (lane 4), but not by competitor DNA containing the Sp1-binding site (lane
5). The Z200E (lane 6) and Z225E (lane 7) proteins bound with efficiency similar to that of the wild-type Z. (B) Nuclear extracts from DG75 cells
transfected with the wild-type Z expression vector (lanes 2–5) and the Z200E expression vector (lanes 6–9) were incubated with double ZRE probe
in electromobility shift assays. Unlabeled AP1 oligonucleotide was added as a competitor at concentrations of 0, 5, 50, and 1001. Lane 1 is the
probe without nuclear extract. The specific Z-binding complex is indicated by the arrow. (C) Nuclear extracts from HeLa cells transfected with the
pHD1013 vector (lane 2), the wild-type Z expression vector (lanes 3 and 4), or the Z200E expression vector (lane 5) were incubated with the double
ZRE probe in electromobility shift assays. The specific Z-binding complex is indicated by the arrow.
negate the effect(s) of a lymphoid-specific Z inhibitor. Z. When R and wild-type Z were cotransfected, trans-
activation of the BMRF1 promoter was 20-fold greaterThe effect of R on the wild-type Z versus the mutant
Z200E protein in Jurkat cells is shown in Fig. 3C. R than that induced by wild-type Z alone. In contrast,
cotransfection of Z200E and R together induced onlyalone had little effect on BMRF1 promoter activity. In
the absence of R, mutant Z200E induced much greater 2.4-fold more transactivation than that observed with
Z200E alone. Furthermore, the level of transactivationtransactivation of the BMRF1 promoter than wild-type
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FIG. 3. Transactivator function of wild-type and mutant Z proteins in different cell lines. (A) The BMRF1-CAT (5 mg) reporter plasmid was
cotransfected with the pHD1013 vector or the wild-type versus mutant Z expression plasmids (2.5 mg each) in Jurkat T cells, DG75 B cells, and
HeLa epithelial cells. The percentage acetylation of chloramphenicol under each condition was determined as previously described (Gorman et
al., 1982). The fold transactivation of BMRF1 promoter activity induced by each Z expression vector (versus the pHD1013 vector) was calculated.
Results are normalized such that the fold activation induced by the wild-type Z vector is set at 100% for each cell line. (B) The BMRF1-CAT (5 mg)
reporter plasmid was cotransfected into Raji cells with the pHD1013 vector, the wild-type Z and mutant Z200E expression vectors alone (1.0 mg),
or the wild-type and mutant Z200E vectors with the p65 expression plasmid (2.5 mg). The transactivator function of wild-type Z and Z200E in the
absence of p65 is normalized as 100% (white bars) and compared to transactivator function in the presence of cotransfected p65 (black bars). (C)
5 mg of the BMRF1-CAT plasmid was cotransfected into Jurkat cells with various combinations of expression plasmids (5 mg each) as follows (left
to right): pHD1013 vector DNA, the R expression vector, the wild-type Z expression vector, the Z200E expression vector, the R and wild-type Z
expression vectors, or the R and mutant Z200E expression vectors. The results are presented as fold activation induced by the various expression
vectors (relative to pHD1013 vector DNA).
induced by the Z wild-type/R combination was not sig- cells and HeLa cells. The Z225E mutant also had sta-
bility similar to that of the wild-type Z (data not shown).nificantly different from that induced by the Z200E/R
combination. Thus, in the presence of R, the transacti-
vation of the BMRF1 promoter by wild-type Z in Z200E-induced transactivation can occur through
lymphoid cells becomes similar to that of Z200E. both DNA-binding and non-DNA-binding mechanisms
A lymphoid-specific increase in Z expression or sta-
bility could explain the observed increase in Z200E In addition to its usual mechanism of transcriptional
activation (which is mediated through direct binding oftransactivator function. To examine this possibility, im-
munoblot analyses were performed on extracts of Z to upstream ZRE/AP1 motifs), Z can also activate tran-
scription of the BZLF1 promoter (Zp) through a mecha-cells transfected with wild-type, versus mutant, Z pro-
teins (Figs. 4A and 4B). The stability of the wild-type nism not requiring direct DNA binding (Flemington et al.,
1994). This second mechanism of Z-induced transcrip-and mutant Z200E proteins was similar in the DG75
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FIG. 4. Protein stability of wild-type Z and mutant Z200E. (A) DG75 cells were transfected with the pHD1013 vector (lanes 1–3), the wild-type Z
expression vector (lanes 4–6), or the Z200E expression vector (lanes 7–9). Five hours posttransfection, cells were treated with cyclohexamide (50
mg/ml). A portion of the transfected cells was harvested immediately prior to adding the cyclohexamide (Time 0) and again at 24 and 48 hr. Cell
proteins were separated on an 8% SDS gel, transferred to a nitrocellulose membrane, and immunoblotted using the anti-Z monoclonal antibody,
BZ.1. The position of Z is indicated by the arrow. (B) HeLa cells were transfected with the pHD1013 vector (lane 1), the wild-type Z expression
vector (lane 2), or the Z200E expression vector (lane 3). Cell lysates were prepared 48 hr after transfection, separated on an SDS–8% polyacrylamide
gel, transferred to nitrocellulose membranes, and subjected to immunoblot analysis using the anti-Z monoclonal antibody, BZ.1. The position of Z
is indicated by the arrow.
tional activation is presumably mediated through interac- tually increases transactivation of the BZLF1 promoter
(Fig. 5B). Similarly, the CMV-Z200E construct containingtions between Z and cellular transcription factors.
The BMRF1 promoter contains two major Z-binding an additional mutation of amino acid 185 (pCMV-Z200E/
311) transactivates the BZLF1 promoter more efficientlysites (an AP1 site located at 060 and a ZRE site located
at 0106), both of which are required for efficient activa- than Z200E (Fig. 5B). As expected, mutation of amino acid
185 inhibits the ability of Z200E to activate the BMRF1tion by wild-type Z (Quinlivan et al., 1993). To determine
if the Z200E protein must bind directly to the BZLF1- promoter (Fig. 5B).
These data suggest that in DG75 cells, the Z200E mu-binding sites in the BMRF1 promoter in order to activate
its transcription, we examined the effects of specific dele- tant is a more efficient transactivator than wild-type Z for
either the direct DNA-binding mechanism of transactiva-tions of the AP1 site alone, the ZRE site alone, or both
sites together. As shown in Fig. 5A, the ability of the tion or the indirect mechanism. Although the precise cel-
lular transcription factor(s) mediating the indirect mecha-mutant Z200E protein to activate the BMRF1 promoter
was significantly decreased if either the AP1 site or the nism of transactivation has not been identified, our re-
sults indicate that the Z200E mutant is still capable ofZRE site was abolished. These results suggest that the
Z200E protein activates the BMRF1 promoter through a interacting with this factor(s).
direct binding mechanism. As is the case for wild-type
Z, binding of the mutant Z200E protein to both the AP1 Wild-type Z and Z200E disrupt viral latency in
site and the ZRE site is required for maximal effect. lymphoid cells with similar efficiency
To examine if Z200E can transactivate the BZLF1 pro-
moter through a non-DNA-binding mechanism, an addi- Expression of wild-type Z in latently infected lymphoid
cells is sufficient to activate lytic infection (Chevallier-tional mutation altering amino acid 185 (a mutation which
is known to abrogate Z DNA binding) (Giot et al., 1991) Greco et al., 1986; Countryman and Miller, 1985; Kenney
et al., 1989b; Rooney et al., 1988, 1989; Takada et al.,was inserted into the CMV-Z200E plasmid. As was the
case with the BMRF1 promoter (Fig. 3A), in the absence 1986). Although the Z200E mutant has greater transacti-
vator function than the wild-type Z in the absence of R,of the 185 mutation, the Z200E mutant activated the
BZLF1 promoter five times more efficiently than wild-type agents which disrupt viral latency appear to activate Z
and R expression simultaneously (Flemington et al.,Z in DG75 cells (Fig. 5B). Mutation of amino acid 185
(plasmid Z311), in the context of the wild-type amino acid 1991b; Laux et al., 1988). Furthermore, we have shown
that transfection of Z into latently infected lymphoid cells200, has been previously shown to inhibit BZLF1-induced
activation of the BMRF1 promoter (Kenney et al., 1992), results in activation of R expression from the endogenous
viral genome (Zalani et al., 1996). Given this ability of Zbut as previously described (Flemington et al., 1994) ac-
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FIG. 5. Z200E can transactivate different promoters by both DNA-binding and non-DNA-binding mechanisms. (A) The wild-type BMRF1-CAT plasmid
(open bars), the BMRF1-DAP1-CAT construct (in which the BMRF1 promoter AP1 site has been specifically mutated) (stippled bars), the BMRF1-DZRE-
CAT construct (in which the BMRF1 promoter ZRE site has been specifically mutated) (hatched bars), and the BMRF1-DAP1/ZRE-CAT construct (containing
mutations in both the AP1 and ZRE sites) (solid bars) were cotransfected with wild-type Z (ZWT), Z200E, or Z225E into DG75 cells. The percentage of
acetylation for each condition was determined and the fold activation induced by the various Z expression vectors (in comparison to pHD1013 vector
DNA) was calculated. Results are normalized such that the fold activation of the parent BMRF1-CAT construct is set at 100% for each Z expression vector.
(B) The Z-CAT plasmid (2.5 mg) (hatched bars), which contains the BZLF1 (Zp) promoter, was cotransfected into DG75 cells with the pHD1013 vector, the
wild-type Z vector (ZWT), the mutant Z311 vector (containing a mutated amino acid 185 and a wild-type amino acid 200), the Z200E expression vector
(containing a wild-type 185 residue and a mutated amino acid 200), or the Z200E/311 vector (containing mutant 185 and 200 residues) (5 mg each). The
BMRF1-CAT plasmid (2.5 mg) (solid bars) was cotransfected with either the Z200E or the Z200E/311 plasmids into DG75 cells. The CAT activity induced
by each expression vectors was calculated by fold activation relative to the pHD1013 vector DNA.
to activate endogenous R expression, disruption of viral The ability of wild-type Z and Z200E to induce lytic
infection in Raji cells (a latently infected Burkittlatency by the wild-type versus Z200E mutants might be
anticipated to be similar. lymphoma line) was compared (Fig. 6). The wild-type
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nism. According to the previously proposed coiled-coil
model for the bZip domain of Z, amino acid 200 would
be located within the hydrophobic interface (position d) of
the first heptad repeat of the putative four or five heptad Z
coiled-coil helix (Chang et al., 1990; Flemington and
Speck, 1991; Kouzarides et al., 1991; Lieberman and
Berk, 1990). It is therefore somewhat surprising that re-
placement of the tyrosine residue normally present at
this position with the charged glutamic acid residue still
allows efficient homodimerization. Although our data are
consistent with the interpretation that p65 interacts di-
rectly with amino acid 200 in Z, we cannot exclude the
possibility that mutation of amino acid 200 subtly alters
Z conformation such that the Z/p65 interaction (mediated
through another residue) cannot occur.FIG. 6. Wild-type Z and mutant Z200E disrupt viral latency with similar
In contrast to amino acid 200, mutation of Z aminoefficiency. Latently infected, EBV-positive Raji cells were transfected
with 5 mg of pHD1013 vector DNA (lane 1), wild-type Z vector (lane 2), acid 225 did not significantly alter its interaction with
or Z200E vector (lane 3). The cells were harvested 2 days after transfec- p65. The transactivator function of Z225E was somewhat
tion and cell lysates were separated by SDS–PAGE, transferred to a impaired relative to that of wild-type Z in epithelial cells,
nitrocellulose membrane, and analyzed by immunoblot using the anti-
but similar to that of wild-type Z in lymphoid cells. AminoZ monoclonal antibody, BZ.1 and the anti-BMRF1 antibody (Capricorn
acid 225, like amino acid 200, is positioned within theProducts, Inc.). The positions of the Z and BMRF1 proteins are indi-
cated. coiled-coil interface (position a) (Flemington and Speck,
1991). Future study will be required to determine if the
Z225E phenotype reflects the loss of a direct interaction
and mutant Z200E expression vectors were trans-
between Z and a cellular protein.
fected into Raji cells, and the amount of lytic viral
Although the Z200E mutant was specifically identified
induction was quantitated by immunoblot analysis us-
in this report for its inability to interact with the p65 com-
ing an antibody specific to the early BMRF1 viral
ponent of NF-kB, amino acid 200 in Z may be involved
protein. As shown in Fig. 6, the wild-type and mu-
in the recognition of other cellular proteins as well, such
tant Z200E expression vectors induced equivalent
as the retinoic acid receptors and p53, both of which
amounts of the early BMRF1 protein.
are known to inhibit Z transactivator function by direct
interaction with the dimerization domain of Z. The Z resi-
DISCUSSION
dues required for direct interaction with p65 are similar,
but not identical, to those required for interaction withEBV infection of B cells and T cells is primarily latent,
in contrast to lytic infection in epithelial cells. The imme- the retinoic acid receptors (Sista et al., 1995). As is the
case for p65, the Z proteins containing the bZip doublediate-early protein, Z, plays a key role in disruption of
viral latency. Z transactivates early viral promoters and mutations, Z197K/200S and Z200E/225E, are unable to
interact directly in vitro with the retinoic acid receptors,initiates the lytic viral cascade. In addition, Z may also
play a direct role in lytic replication (Fixman et al., 1995; although each of these mutants can homodimerize (Sista
et al., 1995). In contrast to our results, the 205R/206DSchepers et al., 1993). Therefore, cellular regulation of Z
is likely to be a crucial factor in determining the strin- mutant is unable to interact with the retinoic acid recep-
tors, although this mutant can interact with p65. It hasgency of viral latency. In this report, we define a region
of Z (amino acid 200 within the bZip dimerization domain) not been determined if the direct interaction between the
RARs and Z is primarily mediated through amino acidwhich negatively regulates Z transactivator function in a
lymphoid-specific fashion. The data presented here also 200, amino acid 225, or both. The precise Z amino acids
required for interaction with p53 have not been identified.suggest that amino acid 200 is a critical site through
which Z interacts with p65 (and perhaps other members The lymphoid-specific phenotype of the Z200E protein,
although potentially mediated through decreased inter-of the rel protein family). Thus, negative regulation of Z
in lymphoid cells may be mediated through direct interac- action with p65, could therefore involve other protein –
protein interactions as well. Furthermore, we cannottion of Z with cellular proteins, including members of the
rel family. completely exclude the possibility that the Z200E muta-
tion, rather than freeing Z from a negative regulator, in-The most intriguing aspect of the Z200E phenotype is
that it increases Z transactivator function in a lymphoid- creases interaction with a positively regulating cellular
factor (such as TFIID) (Chi et al., 1995; Lieberman andspecific fashion. This enhanced transactivation by Z200E
in lymphoid cells occurs with either the direct DNA-bind- Berk, 1991).
A particularly interesting result was the finding thating mechanism of transactivation or the indirect mecha-
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A. (1989). The Epstein–Barr virus (EBV) DR enhancer contains twocotransfected R significantly enhanced the ability of wild-
functionally different domains: Domain A is constitutive and cell spe-type Z to transactivate the early BMRF1 promoter in
cific, domain B is transactivated by the EBV early protein R. J. Virol.
lymphoid cells, while having much less effect on the 63, 615–623.
mutant Z200E protein. Although we have previously Chevallier-Greco, A., Manet, E., Chavrier, P., Mosnier, C., Daillie, J., and
Sergeant, A. (1986). Both Epstein–Barr virus (EBV) encoded trans-shown that direct R binding to the BMRF1 promoter is
acting factors, EB1 and EB2, are required to activate transcriptionrequired for Z/R synergy in lymphoid cells (Quinlivan et
from an early EBV promoter. EMBO J. 5, 3243–3249.al., 1993), the mechanism(s) by which such synergy oc-
Chi, T., Lieberman, P., Ellwood, K., and Carey, M. (1995). A general
curs is not well defined. The Z and R proteins are not mechanism for transcriptional synergy by eukaryotic activators. Na-
known to interact directly. Our data are consistent with ture (London) 377, 254–257.
Countryman, J., and Miller, G. (1985). Activation of expression of latenta model in which the R protein negates the effect of a
Epstein–Barr virus after gene transfer with a small cloned fragmentlymphoid-specific inhibitor of Z. In this model, the Z200E
of heterogeneous viral DNA. Proc. Natl. Acad. Sci. USA 82, 4085–protein, being less susceptible to the putative inhibitor(s),
4089.
would not be as dependent upon R for efficient transacti- Cox, M., Leahy, J., and Hardwick, J. M. (1990). An enhancer within the
vator function in lymphocytes. divergent promoter of Epstein–Barr virus responds synergistically to
the R and Z transactivators. J. Virol. 64, 313–321.Given that Z200E has superior transactivator potential,
Farrell, P., Rowe, D., Rooney, C., and Kouzarides, T. (1989). Epstein–it might be expected that viruses containing this mutation
Barr virus BZLF1 trans-activator specifically binds to consensus Ap1would have a selective advantage in vivo. However, to
site and is related to c-fos. EMBO J. 8, 127–132.
our knowledge, this particular mutation has not yet been Fixman, E., Hayward, G., and Hayward, S. D. (1995). Replication of Ep-
observed in clinical isolates of EBV, suggesting that stein–Barr virus oriLyt: Lack of a dedicated virally encoded origin-
binding protein and dependence on Zta in co-transfection assays. J.Z200E must be inferior to wild-type Z in vivo during some
Virol. 69, 2998–3006.aspect of the viral life cycle. There may be no selective
Flemington, E., and Speck, S. H. (1990). Autoregulation of Epstein–Barradvantage for the Z200E mutant in the context of the
virus putative lytic switch gene BZLF1. J. Virol. 64, 1227–1232.
intact viral genome, given that the R protein appears to Flemington, E., and Speck, S. H. (1991). Evidence for coiled-coil dimer
overcome the lymphoid-specific inhibition of Z function. formation by an Epstein–Barr virus transactivator that lacks a heptad
repeat of leucine residues. Proc. Natl. Acad. Sci. USA 87, 9459–Furthermore, we have recently shown that Z interacts
9463.directly with the viral polymerase processivity factor (the
Flemington, E., Goldfeld, A. E., and Speck, S. H. (1991). Efficient tran-BMRF1 gene product) and that this interaction also re-
scription of the Epstein–Barr virus immediate-early BZLF1 and
quires amino acid 200 (Zhang et al., 1996). In future stud- BRLF1 genes requires protein synthesis. J. Virol. 65, 7073–7077.
ies, it will be important to examine the phenotype of Flemington, E., Lytle, J., Cayrol, C., Borras, A., and Speck, S. (1994).
DNA-binding-defective mutants of the Epstein–Barr virus lytic switchZ200E within the context of the intact viral genome.
activator ZTA transactivate with altered specificities. Mol. Cell. Biol.
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